Tucatinib
Advanced Gastric Cancer
Seagen, a wholly owned subsidiary of PfizerSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Advanced Gastric Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 4 | BBB |
rc48-adc Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | CCC |
su011248 National University Hospital, Singapore | Phase 2 | CCC |
Xmt-1522 Mersana Therapeutics | Phase 1 | CC |
Epcam Car-T Zhejiang University | Phase 1 | CC |
View all 11 →
Same molecule, other indications
Tucatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →